CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
- None.
- None.
WESTPORT, CT / ACCESSWIRE / April 2, 2024 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct", or the "Company"), a precision medicine-based women's health company focused on the development of breast cancer risk assessment and diagnostic tools, today announced positive results from its recent research on breast cancer biomarkers.
The pilot study, utilizing liquid biopsy samples, met its primary endpoint of measuring specific biomarker concentrations demonstrating a significant correlation to predict breast health, and a clinically meaningful improvement compared to measuring one biomarker alone. Overall data results are limited at this time, but a clear positive trend has been observed. Follow-up research will continue to further expand the accuracy and predictability of this breast health assessment platform.
"The study results showing a specific combination of biomarkers could represent a transformative medical advance for breast cancer risk assessment," said Jill Dietz, M.D., CYduct's chief medical officer. "We look forward to expanding our breast health products into the precision medicine risk assessment space and bringing this potentially game-changing new test option to women as quickly as possible."
The ability to detect early warning signals of breast cancer risk with precise "biomarkers," poses significant promise for the early assessment and detection of breast cancer. Theoretically, small tumors can be detected long before they are visible on imaging, which typically requires a tumor to be greater than 5mm in size to definitively identify the tumor.
Dom Gatto, CEO of CYduct Diagnostics stated: "Biomarkers that assess breast cancer, predict breast cancer outcomes and influence treatment choices will play a major role in the future management of breast cancer. CYduct's proposed combination of clinically established breast cancer biomarkers will foster the acceptance of precision medicine-based breast cancer risk assessment and screening programs by creating an individual risk profile, which is irrespective of breast density and interpretation."
About CYduct Diagnostics, Inc.:
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.
Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.
View the original press release on accesswire.com
FAQ
What did CYduct Diagnostics announce regarding breast cancer biomarkers?
What was the primary endpoint of the pilot study?
Who is CYduct's chief medical officer and what did she say about the study results?
What is the potential impact of detecting early warning signals of breast cancer risk with precise biomarkers?
Who is the CEO of CYduct Diagnostics and what did he say about the proposed combination of breast cancer biomarkers?
